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ABSTRACT: Metal−organic framework nanoparticles (nanoMOFs)
have been widely studied in biomedical applications. Although
substantial efforts have been devoted to the development of
biocompatible approaches, the requirement of tedious synthetic steps,
toxic reagents, and limitations on the shelf life of nanoparticles in
solution are still significant barriers to their translation to clinical use. In
this work, we propose a new postsynthetic modification of nanoMOFs
with phosphate-functionalized methoxy polyethylene glycol (mPEG−
PO3) groups which, when combined with lyophilization, leads to the
formation of redispersible solid materials. This approach can serve as a
facile and general formulation method for the storage of bare or drug-
loaded nanoMOFs. The obtained PEGylated nanoMOFs show stable
hydrodynamic diameters, improved colloidal stability, and delayed drug-release kinetics compared to their parent nanoMOFs. Ex situ
characterization and computational studies reveal that PEGylation of PCN-222 proceeds in a two-step fashion. Most importantly,
the lyophilized, PEGylated nanoMOFs can be completely redispersed in water, avoiding common aggregation issues that have
limited the use of MOFs in the biomedical field to the wet forma critical limitation for their translation to clinical use as these
materials can now be stored as dried samples. The in vitro performance of the addition of mPEG−PO3 was confirmed by the
improved intracellular stability and delayed drug-release capability, including lower cytotoxicity compared with that of the bare
nanoMOFs. Furthermore, z-stack confocal microscopy images reveal the colocalization of bare and PEGylated nanoMOFs. This
research highlights a facile PEGylation method with mPEG−PO3, providing new insights into the design of promising nanocarriers
for drug delivery.
■ INTRODUCTION
Metal−organic frameworks (MOFs) have shown great potential
in a variety of applications such as gas storage and separation,1,2
sensing,3 catalysis,4 and drug delivery5−7 due to their well-
defined, tunable structures and permanent porosities. Both the
organic linkers and the inorganic nodes could provide attractive
platforms to incorporate multiple functionalities onto the
MOF’s internal or external surface.8,9 Of particular interest is
the external surface functionalization of nanoMOFs, which has
been extensively explored in biological systems for delivery,
imaging, and therapeutic applications. Functionalization typi-
cally occurs via postsynthetic modifications, which can improve
the colloidal stability and cellular uptake, control drug release,
achieve targeted drug delivery, or prolong circulation time.6 To
date, a number of covalent/coordinative modifications based on
either linkers or nodes have been developed.6,8−10 For example,
Wuttke and Lac̈helt et al. reported a coordinative binding
approach using the high affinity of His-tags toward metal ions.11
We previously reported a click modulation strategy to
functionalize UiO-66 with PEGmoieties using copper(I) iodide
as the catalyst.12 Horcajada et al. developed a graft-fast
functionalization methodology based on aryl radicals to anchor
specific molecules onto the external surface of nanoMOFs.13 In
addition, due to the strong binding affinity between Zr and
phosphate, Gu et al. proposed a unique way to protect a
porphyrinic nanoMOF from being attacked by phosphate ions
using phospholipid bilayers.14 Moreover, the groups ofMirkin et
al.,15 Tan et al.,16 and Farha et al.17 reported strategies to modify
nanoMOFs with phosphate-modified oligonucleotides/DNA.
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Despite the complexity in preparing modified oligonucleotides/
peptides and the introduction of exotic metal species which, in
some cases, give rise to long-term cytotoxicity and poor
biodegradability, these strategies have proved effective in
specific applications. Although great advances have been
achieved, very few functionalization strategies have been
performed under mild conditions, avoiding complicated
synthetic methodologies, costly reagents, or additional toxic
catalysts that are incompatible with the use of biological
macromolecules (e.g., siRNA, proteins) or with the implemen-
tation of good manufacturing practices required for the
translation of MOFs to clinical use (Supplementary Table S1).
External surface modification is often combined with
biocompatible polymers.6,8−10 Among them, polyethylene
glycol (PEG) is one of the most common coatings.18 Ever
since the pioneering work reported by Horcajada and co-
workers, which modified Fe(III)-based nanoMOFs through the
coordination of monomethoxy-amino-PEG to the Fe ions of the
MOF,5 modification with PEG bearing diverse terminal
functional groups, including monovalent PEG carboxylates,19
methoxy PEG−folate,20 and PEG-tailed sulfonate,21 have been
developed. Moreover, among the reportedMOFs, Zr(IV)-based
MOFs have attracted considerable attention because of their
exceptional chemical stability and easy modification with the
desired functionality.22,23 This has made them suitable
candidates for biomedical applications.24 However, very little
attention has been paid to the process of modification.
Remarkably, and although this is generally ignored, in almost
all cases, nanoMOFs-based drug carriers cannot be redispersed
once dried6 and had to be kept in suspension in solution. Again,
this limits their translation into the field of drug delivery, as
nanoMOFs in solutionand especially those loaded with
drugswill show a limited shelf life arising from potential long-
term aggregation and drug release. In view of the existing water-
dispersible technologies based on the radical polymerization of
vinylic groups,13,25 we aimed to develop a formulation strategy
for nanoMOF-based carriers using green and mild conditions,
which can be easily prepared and redispersed.
Here, we report a general formulation strategy for the
solidification of bare or drug-loaded Zr−MOFs through a simple
PEGylation process using methoxy PEG phosphate (mPEG−
PO3, Mn = 5 k)
26 and lyophilization treatment. This strategy
leads to the formation of a low-density solid material, which not
only exhibits excellent water redispersibility at room temper-
ature by mild sonication treatment and maintains the hydro-
dynamic diameter but also shows improved colloidal stability
and delayed drug-release kinetics of the encapsulated model
drug (Scheme 1). In particular, with nanosized PCN-222 as a
model example, we systematically studied the PEGylation
process with mPEG−PO3 using ex situ time-dependent
techniques combined with molecular dynamics (MD) simu-
lations. We also examined the generality and drug storage
capabilities of our formulation strategy by successfully extending
it to other nanosized Zr−MOFs, including UiO-66, MOF-808,
NU-901, and PCN-128 using doxorubicin hydrochloride
(DOX) as a model drug. As a proof-of-concept study, we
selected HeLa cells and demonstrated that the PEGylated-
nanoMOFs exhibited improved intracellular stability and
delayed drug-release capability with less cytotoxicity compared
with bare nanoMOFs. Furthermore, we also studied the
colocalization of bare and PEGylated nanoMOFs through z-
stack confocal microscopy imaging. Overall, we believe our
findings solve a key problem in the evaluation of current MOF-
based drug carriers, as most of them are based on freshly
prepared materials. Indeed, the proposedmaterials andmethods
allow the development of MOF-based drug carriers with
improved shelf lives, making them more desirable for
pharmaceutical exploitation.
Synthesis and Characterization of PCN-222 and PCN-
222@PEG−PO3. We first chose PCN-222 as a representative
Zr−MOF, a material that has been studied extensively for
biological applications due to its large porosity and extraordinary
stability under harsh conditions. PCN-222 consists of Zr6
clusters with eight edges connected to the tetrakis(4-
carboxyphenyl)porphyrin (TCPP) linkers featuring 1D micro-
(triangular) and mesoporous (hexagonal) channels with
diameters of 1.7 and 3.6 nm, respectively.27 Motivated by the
success of a previous modulation strategy,28 we synthesized the
Zr6 clusters first and introduced them to promote the synthesis
of nanosized PCN-222, as heating the solution of TCPP with
ZrCl4 tended to result in mixed phases.
29 Briefly, we prepared
nanosized PCN-222 through a solvothermal reaction between
TCPP and Zr6 clusters using trifluoroacetic acid (TFA) as a
modulator (Figure 1a). In this case, the particle size can be
readily modulated by tuning the amount of TFA employed, an
approach frequently used in the synthesis of other Zr−MOFs.30
With higher amounts of TFA, we isolated PCN-222 with an
increased particle size (Figure S4, see Supporting Information
for full details). For biomedical applications, particle size is
crucial;31 thus, we chose PCN-222 with an average length of
117.8 ± 12.9 nm. Powder X-ray diffraction (PXRD) shows the
presence of broad peaks that match the pattern predicted from
the single-crystal structure, confirming the phase purity of PCN-
222 (Figure 1b). Transmission electron microscopy (TEM)
imaging shows that the PCN-222 nanoparticles have a rod-
shaped morphology and good size uniformity (Figure S5a),
whereas high-angle annular dark-field scanning transmission
electron microscopy (HAADF-STEM) imaging confirms the
Scheme 1. Schematic Illustration of the Synthesis of Redispersible Drug-Loaded NanoMOFs
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existence of highly oriented mesopores (Figure S5b). Dynamic
light scattering (DLS) of PCN-222 shows an average diameter
and polydispersity index of around 118.0 nm and 0.104,
respectively (Figure 1c). In turn, the zeta potential of around
31.7 mV (Figure 1d) suggests that the predominant end groups
on the external surface are the metal units, which could facilitate
the postsynthetic PEGylation with negatively charged mPEG−
PO3.
We next prepared mPEG−PO3 from commercially available
poly(ethylene glycol) methyl ether (Mn = 5 k) (Scheme S1).
NMR spectroscopy and size exclusion chromatography with
multiangle light scattering (SEC-MALS) confirm the formation
and purity of mPEG−PO3 (Figures S1−S3). We performed the
Figure 1. Characterization of PCN-222 and PCN-222@PEG−PO3. (a) Representation of the synthesis. (b) Simulated and experimental PXRD
patterns. (c) Intensity-average diameter of a water suspension of PCN-222 (green line) and PCN-222@PEG−PO3 (blue line) and the redispersed
solution of PCN-222@PEG−PO3 (pink line) in water (n = 3). (d) Zeta potential of water suspensions of PCN-222 and PCN-222@PEG−PO3. (e) 31P
SSNMR spectra. (f)High-resolution Zr 3d spectra. (g) XPS survey spectra. (h) TEM image of drop-cast PCN-222@PEG−PO3. (i) SEM image of
lyophilized PCN-222@PEG−PO3. (j) Photographs of lyophilized PCN-222@PEG−PO3 (left) and its redispersed suspension (right). Scale bar: 500
nm.
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PEGylation of PCN-222 bymixing an aqueous suspension of the
PCN-222 with an aqueous solution of mPEG−PO3 at room
temperature for 16 h followed by centrifugation and dialysis.
The final product was kept in an aqueous suspension.
Importantly, we found that the drying method was critical for
the morphology and characteristics of the final products. If the
resulting suspension was centrifuged and exchanged with
ethanol and then dried in air, a dense and dark-colored sample
was obtained (Figure S6a). On the other hand, if the suspension
was lyophilized, a brown material with low density was isolated
(Figures 1j and S6b). We noted that the ambient-dried material
was largely aggregated, but the lyophilized sample could be
easily redispersed upon sonication, leading to a pink suspension
(Figure 1j, Video S2), which shows the characteristic Tyndall
effect with a passing red laser beam, revealing the colloidal
nature of the redispersed suspension (Figures S22 and S23b).
We denote this newmaterial as PCN-222@PEG−PO3. Table S2
shows that the amount of incorporated mPEG−PO3 in PCN-
222@PEG−PO3 is 32.9 wt %, estimated using inductively
coupled plasma-optical emission spectroscopy (ICP-OES) by
measuring the ratio of P to Zr.
Following the PEGylation process, we characterized the
material to demonstrate the successful incorporation of mPEG−
PO3. PXRD confirms the formation of a crystalline phase, where
the first five peaks match both the parent and the simulated
patterns well, confirming the maintained crystallinity after
PEGylation. A broad new peak at around 2θ = 22.0° and two
new peaks centered at 2θ = 19.0° and 23.2° in ambient-dried and
lyophilized PCN-222@PEG−PO3 were found after PEGylation,
which is due to the formation of amorphous and semicrystalline
PEG in PCN-222@PEG−PO3 (Figures 1b and S24).32,33
However, the first peak became weaker in terms of intensity
after PEGylation. Given that the channels of PCN-222 are large
enough to accommodate linear mPEG molecules,34 we reason
that this feature is probably related to the mPEG that infiltrated
and partially occupied the mesoporous cavities. Fourier
transform infrared (FT-IR) spectra provide further evidence
for the existence of mPEG−PO3, where the appearance of two
new bands at 2866 and 1088 cm−1 are attributed to the
stretching vibrations of C−H and P−O, respectively, from the
mPEG−PO3 molecules (Figure S28a).35 In particular, we
observed a shift in the FT-IR absorption from 1095 to 1088
cm−1 for the P−O bonds in the PCN-222@PEG−PO3
compared to that of mPEG−PO3 (Figure S28b), indicating
the presence of an interaction between the Zr6 cluster and the
phosphate group, consistent with data in previous reports.32,36
TEM imaging of drop-cast PCN-222@PEG−PO3 clearly shows
the well-preserved morphology and monodispersed particles of
the parent MOF (Figure 1h). Moreover, HAADF-STEM
imaging demonstrates the preservation of highly ordered
mesopores after PEGylation (Figure S7). We also employed
DLS to investigate the effect of PEGylation on the dispersity of
PCN-222, obtaining a particle diameter of 129.7 ± 0.9 nm,
which is slightly larger than that of the parent PCN-222 (Figure
1c). On the other hand, the polydispersity index was reduced to
a value of 0.076± 0.004, which can be explained by the fact that
the PEGylation process disperses the initial, existent small
aggregates in the parent PCN-222 sample. Figure 1d shows that
the zeta potential becomes negative, from 31.7± 0.4 mV for the
parent PCN-222 to −43.9 ± 1.2 mV for PCN-222@PEG−PO3,
attributed to the attachment of terminal phosphate groups on
the external surface of the PCN-222 sample.37
We next performed 31P solid-state nuclear magnetic
resonance (SSNMR) and X-ray photoelectron (XPS) spectros-
copies to study the interaction between mPEG−PO3 and the
framework. Figure 1e shows the chemical shift of the
phosphorus resonance in solid-state PCN-222 and PCN-
222@PEG−PO3. Free mPEG−PO3 features a sharp peak at
around −0.30 ppm; after PEGylation, the peak becomes
broadened and upshifts to −8.39 ppm. The broadened peak is
due to the accumulation of the slightly different chemical shifts,
which originate from the location of mPEG−PO3 on different
binding sites of the Zr6 cluster since both the −OH and the
−OH2 groups could provide anchoring sites.8,38 In addition, the
Figure 2. Time-dependent studies of PCN-222@PEG−PO3. (a) Proposed schematic of PCN-222@PEG−PO3 formation. Characterization recorded
at different intervals of time (2, 4, 12, and 16 h). (b) Simulated and experimental PXRD patterns. (c) N2 isotherms at 77 K. (d) PSD obtained with the
NLDFT method.
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shift in the phosphorus resonance suggests an interaction
between the phosphate group of the mPEG−PO3 and the
framework, similar to a previously reported oligonucleotide-
functionalized MOF.15 The XPS survey and high-resolution
scan of the P 2p spectra confirm the existence of P in PCN-222@
PEG−PO3 (Figures 1g and S20), which presumably belongs to
the P of incorporated mPEG−PO3. Furthermore, in the high-
resolution Zr 3d spectra, two main peaks at 184.4 and 182.0 eV,
ascribed to the 3d3/2 and 3d5/2 of Zr(IV) in parent PCN-222,
39
shift to 183.5 and 181.1 eV, respectively (Figure 1f). The shift in
binding energy could mainly be due to the change in the
chemical environment that Zr atoms experience.40 In this case,
replacement of the trifluoroacetate group by the relatively weak
electronegative phosphate moiety in mPEG−PO3 causes a less
electron-withdrawing effect on the Zr6 clusters, resulting in a
negative shift of the XPS peaks for Zr.41 Similar results have been
reported for another Mn-decorated Zr−MOF.42 Figure 1g
shows that the F 1s peak of parent PCN-222 at 688.2 eV is
significantly weakened after PEGylation, suggesting that the
amount of boundTFA decreases. Taken together, the shift of the
chemical resonances15,43 and binding energies36,44 after
PEGylation suggests the formation of the Zr−O−P coordina-
tion bonds.45,46
To better visualize the presence of mPEG−PO3 in PCN-
222@PEG−PO3, we performed SEM on the dried samples. We
clearly observe that nanoMOFs are tightly embedded within the
matrix in the lyophilized PCN-222@PEG−PO3; we hypothesize
that the matrix is formed by the surface-attached mPEG−PO3
molecules (Figures 1i and S8), which can act as spacers, thus
physically isolating the individual PCN-222@PEG−PO3
particles. In contrast, SEM of ambient-dried PCN-222@
PEG−PO3 reveals monodispersed particles randomly packed
into centimeter-sized three-dimensional superstructures (Figure
S9), where the matrix observed in the lyophilized samples
vanishes. This suggests that in the ambient-dried samples, the
mPEG−PO3 molecules closely adhere to the particles; similar
isolated particles were found in previously reported strat-
egies.12,15,47 In addition, the nanoMOFs’ external surface in the
ambient-dried PCN-222@PEG−PO3 becomes rough compared
to the parent PCN-222, as their external surface features become
dominated by the bulk of their capping polymers, which form
nanopapillae.48
We next conducted N2 adsorption experiments at 77 K to
investigate the potential impact of incorporating mPEG−PO3
into the internal porosity of PCN-222. As shown in Figure 2c,
PCN-222 and PCN-222@PEG−PO3 adsorb 526 and 129 cm3
g−1 N2 at P/P0 = 0.8, respectively, with Brunauer−Emmett−
Teller (BET) areas, analyzed using BETSI,49 decreasing from
1151 to 265 m2 g−1 (see Supporting Information, Section S4).
However, the pure mPEG−PO3 adsorbs a nearly negligible
amount of N2 (Figure S33). Assuming that all of the included
mPEG−PO3 molecules are located at the external surface, the
ideal N2 uptake at P/P0 = 0.8 would be 353 cm
3 g−1 after
subtracting the amount of mPEG−PO3 included (Table S3).
The actual value obtained here, however, is only 36.5% of this
ideal N2 uptake where the PEG chains do not affect the internal
porosity of PCN-222. The discrepancy between the ideal value
and the experimental one is most likely due to the infiltration of
mPEG−PO3 molecules into the internal porosity of PCN-222
after performing PEGylation for 16 h. This is quantified further
by the pore size distribution (PSD) obtained using the non-local
density functional theory (NLDFT)method.50 We note that the
calculated average pore size of the parent PCN-222 features two
types of pores at 13 and 27 Å, consistent with reported results.51
The incremental pore volume of PCN-222 greatly reduces after
performing PEGylation for 16 h (Figure 2d), which accounts for
33.5% of that of the parent PCN-222 after correction by
subtracting the amount of mPEG−PO3 included. We also note
that the calculated average pore size slightly decreased by 1.2 Å
(Figure S36). Overall, this reveals a partial infiltration of the
mPEG−PO3 chains, blocking the accessibility of the nitrogen
toward the internal porosity. The results reveal that our method
modifies the external surface with a partial sacrifice of its
porosity.
Time-Dependent PEGylation.Despite the fact that the use
of phosphate-containing PEG for modification of nanoMOFs
has been reported, examples are rare, and the process of
PEGylation is still unclear.26 To better understand the
PEGylation process, we next performed time-dependent studies
on PCN-222 by quenching the PEGylation with centrifugation
and dialysis at different reaction times and analyzing the
intermediates with a number of ex situ spectroscopic and
microscopic methods. We named these obtained PEGylated
PCN-222 as PEGylation x h, where x is the reaction time (x = 2,
4, 12, and 16). Figures 2b and S28 show no significant change in
their PXRD patterns and FT-IR spectra after 2 h. ICP-OES
quantifies the amount of mPEG−PO3 at different PEGylation
times by measuring the ratio of Zr to P (Table S2). The results
show rapid incorporation of mPEG−PO3; the loading of
mPEG−PO3 reaches 27.8 wt % after 2 h. With increased
reaction time, the values reach a plateau at around ∼33 wt %. In
addition, TGA profiles show a similar trend (Figure S26); we
also note that PEGylated PCN-222 is less thermally stable than
the parent PCN-222, which is probably due to the movement
and decomposition of the attached PEG chains.52 We next
examined their N2 adsorption isotherms to investigate the
location of mPEG−PO3 at different reaction times. After 2 h, the
N2 uptake at P/P0 = 0.8 decreases from 526 cm
3 g−1 for the
parent PCN-222 to 348 cm3 g−1 (Figure 2c), accounting for
91.6% of the ideal N2 uptake (Table S3) with a BET area of 756
m2 g−1. The effect of mPEG−PO3 over porosity after 2 h can be
more easily observed after normalizing the N2 isotherms using
the MOF mass only. As shown in Figures 2d and S34, N2
adsorption shows only a small decrease in uptake, while the
shape of its PSD and the calculated average pore size match with
that of the parent PCN-222 very well, with the incremental pore
volume accounting for roughly 90% of that of the parent PCN-
222. We attribute this to the fact that mPEG−PO3 completely
blocks the porosity of few MOF particles and leaves the rest of
the particles unaffected. Altogether, these results suggest that
PEGylation mainly occurs on the surface at the early stage while
not significantly affecting its internal porosity. Afterwards, with
continuous PEGylation for 4 h, the amount of mPEG−PO3
increases up to 33.3 wt % (Table S2), the corresponding N2
uptakes at P/P0 = 0.8 and BET area decrease to 124 cm
3 g−1 and
252 m2 g−1, respectively. The N2 uptakes at P/P0 = 0.8 obtained
accounts for 35.3% of the ideal N2 uptake, and these values
become constant even after prolonging the reaction times to 12
and 16 h (Table S3), indicating that PEGylation has reached an
equilibrium with a large number of mPEG−PO3 molecules
entering the porosity. We assume that the excess of mPEG−PO3
molecules starts to infiltrate into the channel after fully
occupying the available binding sites at the external surface. In
addition, the incremental pore volume decreases greatly,
whereas the calculated average pore size reduces slightly after
performing PEGylation for 4 h and more (Figures 2d and S35a).
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Again, after normalizing the N2 isotherms by subtracting the
amount of mPEG−PO3 included (Figure S35b), we evaluated
the loss of porosity as a function of reaction time on the basis of
the roughly same amount of mPEG−PO3 included (Figure
S38). From this plot we can clearly see a 53.9% loss of porosity
after performing PEGylation for 4 h and then a gradual increase
to around 60% in the following 8 h before reaching a plateau,
suggesting the infiltration of mPEG−PO3 into the internal
porosity, thus partially blocking the pore. Combined with the
results that the loading of mPEG−PO3 is consistent after 4 h
(Table S2), here we attribute the loss of porosity after 4 h to the
dangling PEG chains of surface-bonded mPEG−PO3 infiltrating
into the porosity. Taken together and based on the above results,
we propose a two-step PEGylation process for PCN-222 with
mPEG−PO3, this is, the PEGylation takes place first at the
external surface, probably due to the electrostatic interaction
between positively charged PCN-222 and negatively charged
mPEG−PO3.53 After occupying the available binding sites at the
external surface, the unreacted mPEG−PO3 molecules start to
enter the internal channel of PCN-222, thus partially blocking
the porosity (Figure 2a).
Considering the presence of P in mPEG−PO3, we next
conducted the elemental mapping of the samples employing
energy-dispersive X-ray (EDX) spectroscopy with STEM. In our
case, since the Lα line for Zr is 2.042 keV and the Kα line for P is
2.012 keV,54 the energy window created for P would overlap
with that of the Zr signal, thus leading to misidentification of the
elements.55 Although correction can be performed by
subtracting the contribution of the overlapping peak, it should
be avoided in view of the uncertainties in the correction.56 We
addressed this issue by simply replacing Zr-based PCN-222 with
Hf-based PCN-222, denoted as PCN-222(Hf), whose lines are
separate from those of P and Zr.54 PXRD and N2 adsorption
confirm the crystallinity and porosity of PCN-222 (Hf) (Figures
3a and S37), whereas STEM imaging and the XPS spectrum
clearly show the rod morphology of PCN-222 (Hf) and the
presence of Hf (Figures 3b and S21). Under identical
PEGylation conditions as those of Zr-based PCN-222, we
obtained the ex situ STEM-EDX of PCN-222 (Hf) after 2, 4, 12,
and 16 h, which canmap out the distribution of P andHf. After 2
h, Figure 3c shows that the signal of Hf is evenly distributed
throughout the whole particle, whereas the P signal mainly
originates from the edges; this provides further evidence to
demonstrate that the mPEG−PO3 molecules mainly graft the
external surface at the early stage.With the increment of reaction
time from 4 to 16 h, Figure 3d−f shows that P signals are
uniformly distributed throughout the whole particle. In addition,
we also performed EDX line scans for PCN-222(Hf) after
PEGylation of 16 h, which demonstrates the homogeneous
distribution of Hf and P along the single particle (Figure S19).
The results observed here are consistent with TGA, N2
adsorption, and ICP-OES as mentioned above, which firmly
confirms our hypothesis that the PEGylation of PCN-222 with
mPEG−PO3 proceeds in a stepwise fashion (Figure 2a).
Figure 3. (a) Simulated and experimental PXRD patterns of PCN-222 (Hf). (b) HAADF-STEM image of PCN-222 (Hf). Scale bar: 500 nm. (c−f)
HAADF-STEM images and EDX elemental maps of O, Hf, P, and overlappedHf and P recorded at different reaction times: (c) 2, (d) 4, (e) 12, and (f)
16 h. Scale bar: 50 nm.
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Molecular Dynamics (MD) Simulations. We next
performed MD simulations to investigate the PEGylation
process; this allows us to gain insights into how the presence
of mPEG−PO3 affects the energetics of the whole system (see
Supporting Information, Video S1). Figure 4a shows the
cumulative average total energy of the system decreasing
continuously as a mPEG−PO3 molecule approaches the Zr
atom on the external surface of the framework, suggesting the
PEGylation process is energetically favorable. We note that the
total instantaneous energy of the system stabilizes after mPEG−
PO3 reaches the surface of the framework, indicating that this is
an energetic minimum, equilibrium position of mPEG−PO3.
We also note some metastable equilibrium states, but the
average distance between the phosphate group of mPEG−PO3
and Zr (on the surface of the framework) remains constant. This
implies that the change in the equilibrium state is due to the
conformational rearrangements of the PEG chain on the surface
of the framework.57 Figure 4b shows the position of mPEG−
PO3 relative to the framework as the simulation proceeds. At
0.01 ns, one can clearly see mPEG−PO3 reaching the surface of
the framework and the phosphate group of the mPEG−PO3
anchoring itself to the Zr on the surface of the framework.
Further analysis of the trajectories (Figure S46) tells us that only
parts of the PEG chain dangle into the pores of the framework, as
can be seen from Figure 4b at 0.1 ns, while the remaining large
part of the PEG chain exists as a coil at the external surface. This
behavior is in line with our hypothesis that the majority of
mPEG−PO3 does not enter the pore but anchors itself at the Zr
site on the surface of the framework at an early stage.
Generality of the PEGylation Method and DOX
Encapsulation. We next explored the generality of these
findings to a broader scope of Zr(IV)-based MOFs, including
UiO-66, MOF-808, NU-901, and PCN-128 (Figures 5a and
S10). Remarkably, MOFs with distinct pore sizes and
morphologies were all tolerated, and we successfully obtained
the related lyophilized PEGylated MOFs, denoted as MOF@
PEG−PO3, by following the same procedure as that of PCN-
222. Figure S23a and S23b shows pronounced Tyndall
phenomena for bare nanoMOFs and their PEGylated analogues.
Figure 5d shows the retention of crystallinities and the presence
of semicrystalline PEG after PEGylation, as proven by the PXRD
tests. N2 adsorption isotherms and PSD show that the porosities
are all partially blocked by the infiltrated mPEG−PO3, similar to
what was observed for PCN-222@PEG−PO3 (Figure S39).
Attempts to recover the blocked porosities by thermal
decomposition of the incorporated mPEG−PO3 molecules
were unsuccessful, as MOF@PEG−PO3 lost their crystallinities
after treatment at 300 °C (Figure S24). The loadings of
incorporated mPEG−PO3 molecules evaluated by ICP-OES are
37.7, 38.5, 30.6, and 34.1 wt % for UiO-66@PEG−PO3, MOF-
808@PEG−PO3, NU-901@PEG−PO3, and PCN-128@PEG−
PO3, respectively (Table S2). All of the lyophilized MOF@
PEG−PO3 have low densities (Figure 5b). The SEM images of
the lyophilizedMOF@PEG−PO3 exhibit a uniform distribution
of particles within the matrix formed by incorporated mPEG−
PO3 molecules (Figures S11−S14). Most importantly, all of
them can be redispersed easily after mild sonication treatment,
and we cannot observe any significant difference in their
hydrodynamic diameters compared with the suspensions before
lyophilization (Figures 5e, S23b, and S41 and Videos S2 and
S3). We also evaluated the colloidal stability of these MOF@
PEG−PO3 in water and PBS (pH = 7.4). Figure S43 shows that
the suspensions of PEGylatedMOFs in water can be stable up to
7 days without significant changes in their hydrodynamic sizes.
Although the sizes started to increase after 7 days, it still
outperforms the corresponding bare MOFs, which aggregate in
1 day. In the case of PBS, we note that the pH has a dramatic
impact on the colloidal stabilities of PEGylatedMOFs. As shown
in Figure S44, MOF@PEG−PO3 can maintain their hydro-
dynamic sizes at most for 36 h at pH 7.4. However, the
aggregation rate increased rapidly in pH 6.4 and 8.4 PBS. For
comparison, the bare MOFs aggregate dramatically in a very
short time in pH 7.4 PBS (Figure S43), which limit their further
in vitro use. Altogether, these results suggest that our
PEGylation method can act as a versatile strategy to slow
down the aggregation in water and PBS buffer.
Previously, we developed partial or complete amorphization
strategies to prevent the burst release.58,59 In these approaches,
the collapsed porosities could trap the drug molecules inside the
nanoMOFs, prolonging their diffusion times through the
collapsed pore. Similarly, we hypothesize herein that the
infiltrated mPEG−PO3 molecules could block the drug
molecules within the pore, thus providing the possibility of
prolonging the diffusion time and slowing down the release of
the encapsulated drugs. With these considerations in mind, we
Figure 4. Molecular dynamics simulations. (a) Calculated energy and
distance relative to the framework as a function of time steps. (Left y
axis) Total energy in kcal/mol. (Right y axis) Distance between the
phosphate group and the Zr atom (Angstroms). (x axis) Time step is
plotted in femtoseconds. Light pink points represent the instantaneous
total energy, and pink points represent the cumulative average total
energy computed at every time step. Blue hollow points represent the
instantaneous distance, and blue points represent the cumulative
average distance computed every 10 000 time steps. (b) Position of the
mPEG−PO3 relative to the framework as a function of time. PEG atoms
are in green, phosphate group is in yellow, framework atoms are in
turquoise (translucent), and Zr atoms of the framework are in brown.
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next investigated the effect of the infiltrated mPEG−PO3
molecules upon drug loading and release.
Using the above nanoMOFs as the model platforms, we chose
DOX, an anticancer drug, as a model to examine the loading
capacity and release profile. One critical question here is the
partially blocked porosities by the infiltrated mPEG−PO3
molecules, which may further limit its application in loading
any drug molecules. First, when performing the drug
encapsulation on the lyophilized MOF@PEG−PO3, we found
negligible amounts (less than 1 wt %) of DOX loaded. This
suggests that the infiltrated mPEG−PO3 molecules block access
to the internal porosities. Then, we carried out the drug loading
before performing PEGylation. Briefly, mixing the suspension of
nanoMOFs with an aqueous solution of DOX afforded the drug-
loaded nanoMOFs, followed by the addition of an aqueous
solution of mPEG−PO3, dialysis, and lyophilization. We
obtained the DOX-loaded nanoMOFs and denote them and
the PEGylated nanoMOFs as DOX@MOF and DOX@MOF@
PEG−PO3. Successful DOX encapsulations were indicated by
changes in the nanoMOFs color (Figures 5b and S11−S15). As
verified by UV−vis spectroscopy, 17.6, 14.4, 22.2, 18.1, and 23.2
wt % loadings of encapsulated DOX were obtained for the bare
UiO-66, MOF-808, NU-901, PCN-128, and PCN-222,
respectively. We also observed a slight decrease to 15.1, 13.4,
20.2, 13.6, and 15.5 wt %, respectively, after PEGylation (Figure
S29 and Table S4), likely due to partial infiltration of mPEG−
PO3 in the porosity. For simplification, we denote these
materials as DOX@66@PEG−PO3, DOX@808@PEG−PO3,
DOX@901@PEG−PO3, DOX@128@PEG−PO, and DOX@
222@PEG−PO3. The PXRD patterns confirm that the
Figure 5. Characterization of MOF@PEG−PO3 and DOX@MOF@PEG−PO3. (a) Chemical structures of nanoMOFs. (b) Photographs of
lyophilized MOF@PEG−PO3 (left) and DOX@MOF@PEG−PO3 (right). (c) SEM images of lyophilized DOX@MOF@PEG−PO3. (d) Simulated
and experimental PXRD patterns. (e) Intensity-average diameter of the aqueous suspension of parent nanoMOFs (green line), lyophilized MOF@
PEG−PO3 (pink line), and DOX@MOF@PEG−PO3 (blue line) (n = 3). Scale bar: 1 μm.
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crystallinities remain intact after the DOX loading, and two new
peaks at 2θ = 19.0° and 23.2° appear after the PEGylation,
similar to that of MOF@PEG−PO3 (Figure 5d). The presence
of the characteristic absorption peaks in the UV−vis spectra near
486 nm of DOX in DOX@MOF@PEG−PO3 and the FT-IR
peaks at 1280 cm−1 (C−O−C, stretching vibration) in DOX@
MOF and DOX@MOF@PEG−PO3 indicate the successful
incorporation of DOX molecules (Figures S28 and S30).60 The
N2 isotherms show that all of the DOX@MOFs exhibit a
decrease in the BET areas and pore volumes after the
introduction of DOX molecules (Figure S40 and Table S4).
These results are consistent with the idea that a considerable
portion of the DOX molecules occupy the internal porosity. We
also note that the DOXmolecule with a size of 10.3 Å× 15.8 Å is
difficult to pass through the opening window of UiO-66 (Figure
S27).61 However, we still achieved 17.6 and 15.1 wt % DOX
loading in the case of DOX@UiO-66 and DOX@66@PEG−
PO3 together with the mostly maintained PSD; this is likely due
to the DOX molecules being mainly located at the defect sites
and external surfaces. The following PEGylation leads to further
loss of porosities (Figure S40), consistent with the above result
of MOF@PEG−PO3 in which the drug molecules were not
incorporated (Figure 2c and 2d). Expectedly, all of the
lyophilized DOX@MOF@PEG−PO3 exhibit strong Tyndall
effects and excellent redispersity, comparable to that of MOF@
PEG−PO3 (Figures 5e, S23c, and S41 and Videos S2 and S3). It
should be noted that nanoMOFs have been extensively studied
as drug carriers, but none of them focused on the final
formulation of the MOF−drug composites, which have the
capability of long-term storage while maintaining the original
hydrodynamic sizes.
We also performed grand canonical Monte Carlo (GCMC)
simulations to investigate the adsorption of DOX in these five
bare nanoMOFs (see Supporting Information, Section S5). The
maximum DOX loadings were calculated to be 48.7, 34.6, 67.0,
and 56.5 wt % for the bare MOF-808, NU-901, PCN-128, and
PCN-222, respectively. In the case of DOX encapsulation in the
UiO-66 model, we obtained zero uptake due to the mismatched
sizes (Table S4), which further validates our hypothesis that the
adsorption of DOX molecules occurs at the defect sites or
external surfaces. Figures S47−S50 show the snapshots of the
adsorption process of DOX at low, medium, and saturated
loadings, which clearly exhibit the adsorption behavior of DOX.
Briefly, DOX molecules are first adsorbed on the walls of the
frameworks at low loadings before filling up the whole cavity at
higher loadings. As for PCN-128 and PCN-222, which contain
both micro- and mesoporous channels, DOX molecules tend to
fill the bigger pore first at low loadings followed by the smaller
pore (Figures S49 and S50).
We next investigated the effect of the incorporated mPEG−
PO3 on DOX release behavior in PBS (pH = 7.4). We chose
drug-containing UiO-66, NU-901, PCN-128, and PCN-222 and
the related PEGylated counterparts to compare their cumulative
release. Figure S45 shows the release kinetics of DOX@MOF
and DOX@MOF@PEG−PO3. In the case of UiO-66, we
observed a rapid release of DOX in both PEGylated and bare
UiO-66, and no significant differences were found in their
release kinetics in 200 h (Figure S45a). This is most likely owing
to the fact that DOX is attached to the external surface,
consistent with their mismatched sizes (Figure S27). As for the
other three MOFs (NU-901, PCN-128, and PCN-222), the
release profiles of the PEGylated nanoMOFs show a delay
compared to that of the bare ones. In particular, during the first 6
h, less than ∼20% of DOX was released whereas the bare
nanoMOFs released 38.4%, 52.5%, and 40.1%. Having
demonstrated the delayed release with the presence of
mPEG−PO3, we also tested the time-dependent stabilities of
DOX-loaded bare and PEGylated MOFs in water and PBS (pH
= 7.4). As shown in Figures S16 and S25, both bare and
PEGylated MOFs remained stable in water after 14 days.
However, in the case of PBS (pH = 7.4), bare MOFs
decomposed rapidly after 2 h and degraded mostly at 12 h
while the morphologies of PEGylated MOFs can be maintained
up to 36 h. Afterwards, the particles began to degrade or
aggregate (Figure S17), as confirmed by their PXRD patterns
(Figure S25).We attribute the enhanced stabilities of PEGylated
MOFs to the protection of mPEG−PO3, which serves as a shield
around the MOF particles. In addition, to demonstrate the
retention of framework integrity and porosity of PEGylated
MOFs after treatment with PBS (pH = 7.4), we collected EM
images using cryogenic electron microscopy (cryo-EM), where
the cryogenic temperature can reduce radiation damage induced
Figure 6.Cytotoxicity of bare nanoMOFs andMOF@PEG−PO3. HeLa cells’ viability wasmeasured byMTS assay after a 72 h incubation of (a) PCN-
128 vs PCN-128@PEG−PO3 and (b) PCN-222 vs PCN-222@PEG−PO3 at the same concentration based on nanoMOFs. Statistical analyses for bare
PCN-128 and PCN-222 between each concentration and control are annotated with bars. Separate statistical analysis using a paired t test was
performed between bare PCN-128/PCN-222 and their PEGylated counterpart at a given concentration, as shown directly above the grouped boxplot
accordingly (n = 3; *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05).
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by the electron beam. Figure S18 shows the cryo-EM images of
PBS-treated (pH = 7.4, 24 h) UiO-66@PEG−PO3 and PCN-
222@PEG−PO3, which clearly indicates the preserved ordered
channels and also suggests that PEGylation with mPEG−PO3
does not even partially decompose the internal porosities.
Altogether, these results demonstrate that our PEGylation
strategy can provide a protective shield around nanoMOFs,
which simultaneously prevents the frameworks from rapid
Figure 7. Cellular uptake of PCN-128, PCN-128@PEG−PO3, PCN-222, and PCN-222@PEG−PO3. (a) Flow cytometry analysis of HeLa cells
treated with bare and PEGylated nanoMOFs at equivalent nanoMOF concentrations of 10 μg/mL. (b) Orthogonal projections of z-stack confocal
slices of single HeLa cells counterstained for the cell surface membrane (in white) with nanoMOFs colored in violet. Orthogonal images are shown in
transverse (x/y), sagittal (x/z), and frontal (y/z) views with yellow arrows indicating nanoMOFs that reside inside the cell membrane boundary (see
Supporting Information for full z stacks and Videos S4, S5, S6, and S7). Scale bar: 10 μm.
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degradation and achieves controllable drug release. Most
importantly, this can be a feasible way for the long-term storage
of MOF-based drug carriers.
Cytotoxicity and Cellular Uptake. Following the release
analysis, we next chose PCN-222 vs PCN-222@PEG−PO3 and
PCN-128 vs PCN-128@PEG−PO3 as models for in vitro
studies due to their fluorescent nature and large accessible
porosity. We first evaluated the cytotoxicity of bare and
PEGylated nanoMOFs by 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) assay. As shown in Figure 6a, bare PCN-128 shows
significant cytotoxicity at concentrations of 50, 75, and 100 μg/
mL and 72 h, followed by a sharp fall in viability at an extremely
high concentration of 500 μg/mL. As for the bare PCN-222, we
observed a similar trend, where it seemed to be biocompatible at
concentrations below 100 μg/mL (Figure 6b), but the cytotoxic
effect was also observed at 500 μg/mL for 72 h. Dose-dependent
toxicity has recently been reported for slightly smaller (15−20
nm diameter) zirconia oxide nanoparticles (ZrO2NPs) with
toxicity evident at much lower concentrations than the Zr−
MOFs we examined using a cell line.62 Similar findings to our
ownwere reported byWang et al. also using a cancer-derived cell
line. This group reported 80% viability up to a concentration of
100 μg/mL for a similar porphyrinic Zr−MOF.63 In contrast
with bare MOFs, we did not observe any significant differences
in viability for HeLa cells treated with PCN-128@PEG−PO3
and PCN-222@PEG−PO3, with viability remaining above 80%
at any tested concentration of PEGylated nanoMOFs for 72 h
exposure (Figure 6). At high concentrations, 50 μg/mL and
above, we observed a significant increase in viability for PCN-
128@PEG−PO3 compared to bare PCN-128. Importantly,
PEGylation also solved PCN-222’s toxicity compared to its bare
PCN-222 counterpart at 500 μg/mL. The cytotoxicity of bare
nanoMOFs could be due to the poor colloidal stability and
cationic surface charge, which promote aggregation and disrupt
cellular integrity.64 We hypothesize that the shielding of
nanoMOFs’ external surface charge by PEGylation improves
their biocompatibility and colloidal stability in solution, as
described by others.65,66
We then compared the cellular uptake of PCN-128 and PCN-
222 and their PEGylated counterparts by flow cytometry and
confocal laser scanning microscopy. HeLa cells were treated
with either bare nanoMOFs or PEGylated MOFs for 0.5, 1, 3, 6,
24, and 72 h before being detached from the plate for flow
cytometry analysis (Figure S51). As shown in Figure 7a, we
observed an immediate uptake for the bare PCN-128 with a
sharp increase of cells associated in the first 6 h, which continues
to rise until 24 h. In comparison, PCN-128@PEG−PO3 shows a
much slower increase in cellular affinity over time until 24 h,
where the percentage of cells associated with PCN-128@PEG−
PO3 remains the same afterwards. This effect is less profound in
PCN-222, where cell affinities for bare PCN-222 and PCN-
222@PEG−PO3 at 24 h were similar. Cellular uptake of
nanoparticles can be influenced by many properties of the
nanoparticle, such as size, shape, charge, and surface chemistry.
Both bare PCN-128 and PCN-222 are rod-shaped nanoparticles
with similar charge and particle size, but their linkers constitute
different external surfaces on the nanoparticle.67 This could
subsequently lead to different interfacial interactions between
bare nanoMOFs and proteins,68,69 which may possibly account
for the extremely high cellular association for bare PCN-128 but
not bare PCN-222 in Figure 7. Although PEGylation of
nanoparticles under in vitro conditions has been reported to
show reduced cellular uptake,66,70 the exact reason currently
remains unclear. After PEGylation, nonspecific protein
adsorption could be minimized,71 and in our case, the zeta
potential for PEGylated particles changes from a positively to a
negatively charged surface (Figures 1d and S42), whichmay also
explain the differences in cellular affinity due to the presence of
negatively charged macromolecules at the cell surface.72 To
further assess whether these nanoMOFs are internalized into
cells or are on the external surface, we performed internalization
studies by treating HeLa cells with either bare or PEGylated
nanoMOFs for 24 h (Figure S52). We utilized the optical
sectioning capabilities of the laser scanning confocal microscope
to reconstruct 3D images, which reveal the localization of
nanoMOFs in the interior of the cells. Figure 7b shows
orthogonal projections and 3D visualizations of z-stack images
of cells counterstained with wheat germ agglutinin (WGA,
colored in white) to outline their plasma membranes and the
nanoMOFs (displayed in violet). Both bare PCN-128 and bare
PCN-222 are internalized and accumulated as dim clusters
inside the cells. Notably, we also observed some bare PCN-222
in large clusters located at the surface of the cells and in the
extracellular space on the coverslip, suggesting that bare PCN-
222 aggregated in these locations upon exposure to complete
Figure 8. Cytotoxicity of free DOX, DOX@PCN-128, and DOX@128@PEG−PO3. HeLa cells’ viability was measured by MTS assay after a 72 h
treatment of free DOX, DOX@PCN-128, and DOX@128@PEG−PO3. (a) Freshly prepared stock solutions. (b) Stock solution after being kept at
room temperature for 2 h (n = 4; **** p ≤ 0.0001, *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05).
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cell medium during the 24 h incubation. Indeed, this is
consistent with our previous findings where we showed that bare
MOFs exhibit shorter term dispersity and colloidal stability than
PEGylated ones (Figure S43). In comparison, the internalized
PCN-128@PEG−PO3 and PCN-222@PEG−PO3 appear as
large bright particles in the cytoplasm as well as some diffused
particles inside the cells (Figure 7b).
In Vitro Cytotoxicity of Free DOX, DOX@PCN-128, and
DOX@128@PEG−PO3. In order to avoid the overlap of
absorbance spectra between DOX and nanoMOFs (Figure
S30), we next selected fluorescent PCN-128 to compare the
anticancer efficacy between DOX, DOX@PCN-128, and
DOX@128@PEG−PO3 by MTS assays and IncuCyte for live-
cell imaging, which enables observation of cell behavior over
time by automatically gathering and analyzing images. Briefly,
we prepared free DOX, DOX@PCN-128, and DOX@128@
PEG−PO3 at the same DOX concentration (1 mg/mL) as a
stock solution prior to each experiment, which was either used
immediately or incubated at room temperature for 2 h before
being used in cell culture. The viability was evaluated by MTS
assay after a 72 h treatment. Figure 8 shows that HeLa cells
treated with free DOX exhibited significant toxicity over a 72 h
incubation even at 2 μg/mL, whereas DOX@PCN-128 and
DOX@128@PEG−PO3 had lowerbut a concentration-
dependent trendtoxicity than free DOX with DOX@PCN-
128 being more toxic than DOX@128@PEG−PO3. This
suggests that the presence of mPEG−PO3 has a protective
effect on the encapsulated drug cargo, thus preventing the burst
release, consistent with the release profile (Figure S45c). On the
other hand, when a stock solution of DOX@PCN-128 was used
2 h after its preparation (Figure 8b), its cytotoxicity was more
profound at lower concentrations than if it was used
immediately. In contrast, in the case of DOX@128@PEG−
PO3, the short incubation period did not cause any significant
change in toxicity (Figure 8a). This could be explained by the
DOX-release profiles (Figure S45c), where the burst release of
DOX@PCN-128 provoked a similar effect to that of free DOX,
thereby lessening its capabilities as a controlled-release, drug-
delivery vehicle in comparison to the PEGylated counterpart.
To further examine the effect of released DOX on cell
proliferation, we carried out continuous live-cell imaging at 3 h
intervals over the course of 72 h on HeLa cells treated with free
DOX and DOX-loaded, bare, and PEGylated PCN-128. Figure
9a shows the time-dependent apoptosis of HeLa cells upon
treatment with free DOX, DOX@PCN-128, and DOX@128@
PEG−PO3 at a DOX concentration of 500 ng/mL. HeLa cells
proliferated on the first day of treatment, but the cell count
decreased over time with no significant differences between each
treatment. At a higher DOX dosage of 1 μg/mL (Figure 9b and
Videos S8, S9, and S10), DOX reducedHeLa cells by one-half in
less than 24 h, while in the case of DOX@PCN-128, 50% cell
death was obtained at 48 h. In contrast, cells treated withDOX@
128@PEG−PO3 were able to proliferate initially on day 1, but
some cells seem to struggle later and resulted in cell death. After
further increasing the concentration based on DOX to 5 μg/mL
(Figure 9c and 9d), both DOX and DOX@PCN-128 performed
similarly, causing dramatic cell death in less than 10 h, whereas
DOX@128@PEG−PO3 was capable of slowing down cell death
for 24 h before one-half of the cells were deceased. These results
indicate that both PCN-128 and PCN-128@PEG−PO3 were
capable of delivering their drug cargo DOX and achieve a similar
cytotoxic effect at low concentration. Most importantly,
PEGylated PCN-128, in particular, had the ability to release
encapsulated DOX slowly at a high drug concentration,
highlighting its therapeutic potential for controlled release as a
drug-delivery vehicle.
■ OUTLOOK
We demonstrated the development of a mild and general
strategy for the formulation of Zr−MOFs-based drug carriers by
performing PEGylation in an aqueous mPEG−PO3 solution at
room temperature and drying with lyophilization.We performed
Figure 9. Cell proliferation over a 72 h incubation of DOX, DOX@PCN-128, and DOX@128@PEG−PO3. HeLa cells were treated with DOX,
DOX@PCN-128, and DOX@128@PEG−PO3 and imaged by IncuCyte Zoom every 3 h for a total 72 h incubation. Three different concentrations
were used: (a) 500 ng/mL, (b) 1 μg/mL, and (c) 5 μg/mL. (d) Representative phase-contrast photos of HeLa cells treated with DOX@128@PEG−
PO3 in different concentrations after 72 h (see Videos S8, S9, and S10). Scale bar: 150 μm.
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a series of ex situ characterizations at different reaction times and
MD simulations to systematically study the PEGylation process
of PCN-222. On the basis of these results, we propose a two-step
PEGylation process for PCN-222. First, the mPEG−PO3
molecules bond to the available sites at the surface due to the
electrostatic interactions between positively charged PCN-222
and negatively charged mPEG−PO3; second, after occupying
the available binding sites at the surface, the mPEG−PO3
molecules start to enter the internal channels of PCN-222 and
partially block the porosity. We then extended our formulation
strategy to other Zr-basedMOFs, which have distinct pore sizes,
particle sizes, and morphologies; the obtained PEGylated
nanoMOFs exhibited improved colloidal stabilities in water
and PBS (pH = 7.4) compared to their parent counterparts.
With DOX as a model drug, we tested their application in drug
storage. Most importantly, the lyophilized bare or DOX-
containing PEGylated nanoMOFs showed excellent redispersi-
bility with sonication treatment while maintaining their
hydrodynamic diameters. In vitro studies suggest that the
presence of mPEG−PO3 greatly reduces the cytotoxicities of
nanoMOFs at higher concentrations and avoids the burst release
of the loaded DOX. Using flow cytometry and a series of z-stack
confocal microscopy images, we observed different cellular
affinity and internalization of bare and PEGylated nanoMOFs
within the HeLa cells. Since the majority of established MOF-
based drug-delivery vehicles are kept in wet conditions, this
work for the formulation of redispersible drug-containing MOF
composites not only represents an easy way to increase the
colloidal stability of nanoMOFs and simultaneously endow
them with water redispersibility through the use of a phosphate-
functionalized PEG but also provides inspiration for the storage
ofMOFs-based drug carriers as well as new drug-release options,
which holds great potential for biomedical applications.
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